Greenwich Pharmaceuticals Inc. regulatory update

The Fort Washington, Penn., company received notifications of undisclosed deficiencies from the U.K. and France regarding its PLAs for Therafectin (amiprilose HCl) for rheumatoid arthritis. GRPI also received verbal communication of a deficiency from the Netherlands.

The company plans to seek clarification prior to a formal response. CFO Jeff Randall, who said the deficiencies are similar in nature, said "if any of the deficiencies were so severe as to represent an outright rejection, we'd say so. We don't think that's the case here." ...